Abstract Histone deacetylase inhibitors (HDACi) are a class of compounds that suppress the function of histone deacetylases (HDACs). This study was performed to examine the effects of Trichostatin A (TSA), a typical HDACi, on chondrogenesis of human bone marrow mesenchymal stem cells (hBMMSCs) and related molecular pathways. After evaluating the concentration for cytotoxicity and HDAC activity, hBMMSCs underwent chondrogenic differentiation in pellet culture with or without TSA for 21 days. The weight of TSA-treated pellets was 25% lower than that of untreated pellets. DNA level was not significantly different, but glycosaminoglycan content per DNA level was lower in TSA-treated pellets than that of untreated pellets. Gene expression of the chondrogenic markers (SOX9, Aggrecan, and Col2A1) decreased by by 12.9-fold, 8.9-fold, and 7.6-fold respectively in TSA-treated pellets compared with that in TSA-untreated pellets. TSA-treated pellets had lower cell density and lower proteoglycan staining content compared with those of TSA-untreated pellets. A microarray analysis from TSA-treated pellets showed that 1,467 chondrogenic-related genes were downregulated and 1,524 were upregulated by more than 2-fold compared with TSA-untreated pellets. Col10A1, TGF-b3, and SOX9 decreased significantly by 10-fold, 2.1-fold, and 3.2-fold respectively in TSA-treated pellets compared with those in untreated pellets, whereas expression of BMP4 and FGFR3 increased significantly by 2.1-fold and 5.4-fold respectively. It is concluded that TSA inhibits chondrogenesis and does not seem to be useful for cartilage tissue engineering of hBMMSCs.
Introduction
Articular cartilage has limited capacity for self-repair. Damage to articular cartilage usually leads to osteoarthritis. Recently, cell therapy has been applied to treat hitherto intractable defects in articular cartilage. Of the cell sources, mesenchymal stem cells or mesenchymal stromal cells (MSCs) has been a promising tool for clinical applications in cartilage regeneration [1] . hMSCs (human mesenchymal stem cells) have been extensively studied for chondrogenesis in vitro [2] . Considering that expensive peptide growth factors are necessary for the induction of chondrogenesis from hMSCs, identification of small molecules that can modify chondrogenesis of hMSC may facilitate the potential application of hMSCs for the cartilage repair [3] .
Histone deacetylases (HDAC) are enzymes that silence transcription by modifying chromatin folding. HDAC catalyze the transfer of acetyl groups from acetyl coenzyme A to the e-amino groups of lysine residues in the histone tail, which leads to chromatin condensation, reducing the accessibility of DNA-binding transcription factors [4] . Histone acetylation is closely related to other epigenetic regulation including DNA and histone methylation [2, 5] . Inhibition of HDACs decreases stem cells self-renewal by enhancing expression of differentiation markers [6] and accelerating induced differentiation into osteoblasts [7] . Trichostatin A (TSA) belongs to one of the four classes of histone deacetylase inhibitors (HDACi) and has been used as a therapeutic agent for various cancers [8] [9] [10] . TSA also inhibit the expression of destructive metalloproteinases in chondrocytes, which may make it useful as a chondroprotective agent to treat osteoarthritis [11] . Varying effects of TSA on chondrogenesis were reported. El-Serafi et al. found that TSA enhanced cartilage matrix formation and chondrogenic structure in hBMMSC pellets cultured in chondrogenic media [12] . On the other hand, Wang et al. reported that TSA significantly decreased chondrogenic gene expression and the synthesis of chondrogenic proteins in a dose-dependent manner during transforming growth factor (TGF)-b1-induced chondogenesis by inhibiting of TGF-b1-induced Sp1 expression [3] . To explore the utility of TSA for cartilage tissue engineering, it is necessary to reconfirm the effect of this HDACi on chondrogenesis and the mechanisms underlying the effect. Therefore we investigated the effect of TSA on the chondrogenic differentiation of MSCs and the molecular mechanisms related to TSA treatment. Finally, we analyzed gene expression patterns by TSA in chondrogenesis.
Materials and methods

Cell preparation
Human bone marrow mesenchymal stem cells (hBMMSCs) were purchased from Lonza (Allendale, NJ, USA) and maintained in Minimum Essential Medium Alpha Modification Medium (Welgene Inc., Daegu, Republic of Korea) supplemented with penicillin-streptomycin 100 X (Welgene), and 10% fetal bovine serum (FBS; Gibco, Grand Island, NY, USA). Cells were grown in a CO 2 incubator (Thermo Fisher Scientific, Waltham, MA, USA) at 5% CO 2 atmosphere and 37°C.
Cytotoxicity of TSA (Sigma, St. Louis, MO, USA) on hBMMSCs was measured with the Cell Counting Kit-8 (DOJINDO, ENZO Life Science, Kumamoto, Japan) to define the half maximal inhibitory concentration (IC 50 ) of TSA influencing growth of hBMMSCs (3.3 lM, Fig. 1B ).
HDAC inhibitor activity assay
Cells were seeded at the density of 1 9 10 5 cells in 60 mm dish and were treated with TSA at 0, 0.5, and 5 lM for 72 hrs. The cells were harvested using Histone Deacetylase Assay Kit, Fluorometric (Sigma) and then were analyzed by Microplate spectrophotometer (SpectraMax M3, Molecular Devices, Sunnyvale, CA, USA) with 562 nm laser excitation beam (Fig. 1C) 
Chondrogenic induction of hBMMSCs and TSA treatment
At confluence hBMMSCs were trypsinized and aliquots of 2.5 9 10 5 cells were spun down at 500 g for 10 min and were cultured as pellets. The cells were induced to differentiate in a chondrogenic medium consisting of Dulbecco's modified Eagle's medium/F-12 1:1 Nutrient Mixture (DMEM/F-12) (Welgene) supplemented with 1% v/v 100 9 Insulin-Transferrin-Selenium (Gibco), 75 mg/mL bovine serum albumin (Gibco), 1 mM sodium pyruvate
-7 M (Sigma), and 10 lg/mL recombinant human TGF-b3 (R&D Systems, Minneapolis, MN, USA) and the absence or presence of TSA (3.3 lM).
The media was changed every other day, and the pellets were harvested on day 21. The pellets were washed twice in DPBS and fixed in 4% paraformaldehyde for 1 h. The size (means diameter) and wet weight of the pellets were measured and used for further analysis.
DNA and RNA extraction
Genomic DNA (gDNA) from each pellet for day 21 was prepared using a GeneAll Tissue SV mini Kit (GeneAll, Seoul, Korea) in accordance with the manufacturer's instructions. DNA content was determined by a nanophotometer (Implen, Inc., Westlake Village, CA, USA). Total RNA was extracted on day 14 by TRIzol Reagent (Thermo Fisher Scientific, Waltham, MA, USA). complementary DNA (cDNA) was synthesized from total RNA using the Maxime RT oligo(dT) preMix kit (iNtRON Biotechnology, Seongnam-si, Korea) according to the manufacturer's instructions. Quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR) was performed on the Rotor-Gene Q 5 plex PCR cycler (Qiagen, Hilden, Germany). All samples were evaluated in triplicate.
Glycosaminoglycan contents and histology
Glycosaminoglycan (GAG) content was determined with a Blyscan kit (Biocolor life science, Carrickfergus, UK) in accordance with the manufacturer's protocol. GAG content is described as GAG (lg) per DNA (lg).
After inducing chondrogenesis for 21 days, the pellets were harvested and analyzed. The fixed pellets were prepared for paraffin embedding, and 4 lm thick sections were subjected to Safranin-O, Alcian blue, and hematoxylin and eosin (H&E) staining to verify chondrogenic differentiation of hBMMSCs.
Gene expression profiling with oligonucleotide microarray
After the fragmented cRNA was prepared, it was resuspended in 2 9 hybridization buffer and pipetted onto the assembled Agilent Human Whole Genome 44 K (V2) microarray. The arrays were hybridized for 17 h at 65°C using the Agilent Hybridization oven (Agilent Technologies, Santa Clara, CA, USA). The hybridized microarrays were washed using the manufacturer's washing protocol (Agilent Technologies). The microarray images were scanned with the Agilent DNA microarray Scanner, and the data were quantified using Agilent Feature Extraction software 9.3.2.1. All data were normalized using the intensity-dependent normalization method (locally weighted scatterplot smoothing). The averages of the normalized ratios were calculated by dividing the average of the normalized signal channel intensity by the average of the normalized control channel intensity. GeneSpringGX 7.3.1 (Agilent Technologies) was used to select the genes that showed more than two-fold differences in expression.
Quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR) analysis
We selected three chondrogenic markers (SOX9, Aggrecan, and Col2A1) to evaluate chondrogenesis. We selected upregulated BMP4 and FGFR3 and downregulated genes (Col10A1, SOX9 and TGF-b3) by TSA treatment from the microarray results in order to confirm gene expression profiling. The qRT-PCR reaction conditions were as follows: activation for 10 min at 95°C and denaturation 45 cycles for 5 s at 95°C on each cycle, annealing for 10 s at 60°C, and extension for 15 s at 72°C. For PCR amplification, Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an internal control and the primers are provided in supplemental Table S1 . The cycle threshold (Ct) value of each gene was estimated for each reverse transcript sample. All executed experiments were performed in triplicate.
Statistical analysis
All data were expressed as mean ± standard deviation. Statistical comparisons were made using the Mann-Whitney U-test and SPSS 15.0 software (SPSS Inc., Chicago, IL, USA). The Statistical significant p values were set at p \ 0.05.
Results
Cell viability and HDAC inhibition by TSA
Cytotoxicity of TSA was measured for 24 h and 72 h. At 24 h, cytotoxicity of TSA was definite from the concentration of 50 lM. The IC 50 (72 h) value of TSA after treating the hBMMSCs for 72 h was 3.3 lM (Fig. 1B) . HDAC activity was suppressed by 26% at 0.5 lM and by 41% at 5 lM (Fig. 1C) . This concentration of TSA (3.3 lM) was used in the hBMMSC chondrogenic pellet culture.
TSA inhibits chondrogenic differentiation of hBMMSCs
The pellets treated with TSA had 1.2-fold diameters (p \ 0.05) but the wet weights of the TSA-treated pellets were 25% lower than those of the untreated pellets (p \ 0.05). GAG per DNA level was also 25% lower in TSA-treated pellets than that in TSA-untreated pellets (p \ 0.05), on the other hand, DNA level was no significant difference between TSA-treated pellets and TSA-untreated pellets ( Fig. 2A) . Gene expression of the chondrogenic markers SOX9, Aggrecan, and Col2A1 decreased significantly by 12.9-fold, 8.9-fold, and 7.6-fold in TSA-treated pellets compared with that in TSA-untreated pellets (p \ 0.05) (Fig. 2B) . The H&E, Safranin-O, and Alcian blue staining demonstrated that TSA-treated pellets had lower cell density and lower proteoglycan staining intensity than those of TSA-untreated pellets (Fig. 2C) . Overall, these findings suggest that TSA inhibits chondrogenesis of hBMMSCs.
Microarray reveals upregulated and downregulated gene lists in response to TSA treatment
We performed microarray with mRNA isolated from chondrogenic pellets on day 21. The heat maps, the result of microarray, were subject to a hierarchical clustering analysis. The microarray analysis showed that 1,467 chondrogenic-related genes were downregulated and 1,524 were upregulated by more than two-fold expression differences. Of them, 21 genes have reported to be more closely associated with chondrogenesis ( Fig. 3 and Table 1 ). Of the 21 genes, Col10A1 was downregulated more than 10-fold, TGF-b3 was 2.1-fold downregulated and SOX9 was 3.2-fold downregulated. BMP4 and FGFR3 were upregulated 2.1-fold and 5.4-fold respectively. These five genes (Col10A1, TGF-b3, SOX9, BMP4, and FGFR3) were chosen for the qRT-PCR analysis.
qRT-PCR confirms downregulation of Col10A1
, TGF-b3, and SOX9 and upregulation of BMP4 and FGFR3 by TSA treatment
The microarray results were further confirmed by qRT-PCR of selected genes. Col10A1, TGF-b3 and SOX9 were decreased significantly by 3.3-fold, 9.6-fold and 11-fold respectively in TSA-treated pellets compared with untreated pellets (p \ 0.05) (Fig. 4A) , whereas BMP4 and FGFR3 expression increased significantly by 1.6-fold and 3.3-fold respectively (p \ 0.05) (Fig. 4B) . These mean that TSA caused suppression of TGF-b3 and SOX9, which are key mediators of chondrogenesis, and induction of BMP4 and FGFR3, which promotes osteogenesis.
Discussion
The results show that TSA inhibits chondrogenesis of hBMMSCs, which agrees with those of Wang et al. who showed that TSA has suppressive effect on chondrogenesis rather than enhancing effect. In this sense, TSA is detrimental rather than contributory to cartilage tissue engineering. TSA suppressed expression of SOX9, the key chondrogenic transcription factor, and Col2A1 and Aggrecan, two major cartilage matrix components, as well as decreasing total proteoglycan content in the pellet. These results suggest that TSA is not useful for cartilage tissue engineering of hBMMSCs. One of the key differences between this study and previous studies was the concentration of TSA (3.3 lM) used to treat the hBMMSCs, which was much higher than those (*100 nM) used in previous studies. The high concentration, which was considered cytotoxic, was still used in this study because HDAC was substantially inhibited on that concentration in hBMMSCs. TSA treatment was done in a three-dimensional (3-D) chondrogenic pellet culture model. This model provides different environment from monolayer culture in which most HDACi-related experiments have been performed. A 3-D culture is a standard and necessary condition for chondrogenic differentiation of hBMMSCs. With the pellet culture, we measured the diameter of pellets, and the TSA-treated pellets had greater diameter than TSA-untreated pellets. According to Jahn et al., the formation of a surface fibrous-tissuelike cell layer surrounding the inner cells of the pellets was detected by day 19, and the pellets on day 19 were much smaller than day 7 [13] .
No difference in DNA level was detected between TSAtreated and untreated pellets in the current study, indicating that cell proliferation was not affected by TSA in the chondrogenic pellet culture environment. While the concentration used in the current study not only effectively suppressed HDAC activity but also strongly inhibited cell proliferation in monolayer culture, hBMMSCs were more resistant to the toxicity of TSA in the chondrogenic pellet culture. The relatively hypoxic conditions inside the pellets or components of the chondrogenic medium including TGF-b may have moderated the toxic effect of TSA. Also, activation of proliferative genes, such as BMP4 and FGFR3, may have mitigated the inhibitory effect of TSA on cell proliferation. The microarray results provide a glimpse into the molecular pathways involved in TSA-mediated suppression of chondrogenesis. Although not applicable to all listed genes and genes have several different functions, the suppressed genes which are related to chondrogenic differentiation include SOX9, TGF-b3, SULF1, CTGF, Prrx1. On the other hand, FGFR3, which is related to chondrocyte proliferation, or factors related to osteogenic differentiation, such as BMP4, FRZB, GDF5, and CLEC3B increased. These results suggest that suppression of HDAC by TSA have differential effects on the expression of genes involved in the proliferation and differentiation of hBMMSCs.
The limitation of this study is that only in vitro data was presented to show that TSA inhibits chondrogenesis.
Animal models that can test cartilage regeneration or improvement of osteoarthritis could have strengthened the result of in vitro investigations. Also, an in vitro design that enhances the action of HDAC could have produced interesting results. Still, the findings from this study provide a corroboratory data on the concept that TSA is not useful for cartilage regeneration. In conclusion, TSA inhibits chondrogenesis and is not useful for enhancing cartilage tissue engineering of hBMMSCs. 
